Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1
- PMID: 11793011
- DOI: 10.1038/nature711
Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1
Abstract
Neurofibromatosis type I (NF1) is one of the most common single-gene disorders that causes learning deficits in humans. Mice carrying a heterozygous null mutation of the Nfl gene (Nfl(+/-) show important features of the learning deficits associated with NF1 (ref. 2). Although neurofibromin has several known properties and functions, including Ras GTPase-activating protein activity, adenylyl cyclase modulation and microtubule binding, it is unclear which of these are essential for learning in mice and humans. Here we show that the learning deficits of Nf1(+/-) mice can be rescued by genetic and pharmacological manipulations that decrease Ras function. We also show that the Nf1(+/-) mice have increased GABA (gamma-amino butyric acid)-mediated inhibition and specific deficits in long-term potentiation, both of which can be reversed by decreasing Ras function. Our results indicate that the learning deficits associated with NF1 may be caused by excessive Ras activity, which leads to impairments in long-term potentiation caused by increased GABA-mediated inhibition. Our findings have implications for the development of treatments for learning deficits associated with NF1.
Similar articles
-
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.Curr Biol. 2005 Nov 8;15(21):1961-7. doi: 10.1016/j.cub.2005.09.043. Curr Biol. 2005. PMID: 16271875
-
A mouse model for the learning and memory deficits associated with neurofibromatosis type I.Nat Genet. 1997 Mar;15(3):281-4. doi: 10.1038/ng0397-281. Nat Genet. 1997. PMID: 9054942
-
NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.Circulation. 2007 Nov 6;116(19):2148-56. doi: 10.1161/CIRCULATIONAHA.107.707752. Epub 2007 Oct 22. Circulation. 2007. PMID: 17967772
-
Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1.J Child Neurol. 2002 Aug;17(8):622-6; discussion 627-9, 646-51. doi: 10.1177/088307380201700813. J Child Neurol. 2002. PMID: 12403561 Review.
-
Recent developments in neurofibromatosis type 1.Curr Opin Neurol. 2007 Apr;20(2):135-41. doi: 10.1097/WCO.0b013e3280895da8. Curr Opin Neurol. 2007. PMID: 17351482 Review.
Cited by
-
Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.J Cereb Blood Flow Metab. 2015 Aug;35(8):1304-12. doi: 10.1038/jcbfm.2015.43. Epub 2015 Mar 18. J Cereb Blood Flow Metab. 2015. PMID: 25785829 Free PMC article.
-
Steady-state visual evoked potentials in children with neurofibromatosis type 1: associations with behavioral rating scales and impact of psychostimulant medication.J Neurodev Disord. 2022 Jul 22;14(1):42. doi: 10.1186/s11689-022-09452-y. J Neurodev Disord. 2022. PMID: 35869419 Free PMC article.
-
Neural phenotypes of common and rare genetic variants.Biol Psychol. 2008 Sep;79(1):43-57. doi: 10.1016/j.biopsycho.2008.02.005. Epub 2008 Feb 23. Biol Psychol. 2008. PMID: 18395317 Free PMC article. Review.
-
Cognitive genomics: Searching for the genetic roots of neuropsychological functioning.Neuropsychology. 2017 Nov;31(8):1003-1019. doi: 10.1037/neu0000412. Neuropsychology. 2017. PMID: 29376674 Free PMC article. Review.
-
Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.JAMA. 2008 Jul 16;300(3):287-94. doi: 10.1001/jama.300.3.287. JAMA. 2008. PMID: 18632543 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
